$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Avatrombopag usage and dosage guide, what key points patients need to know
2026-02-01 22:25:32
Check Details
Domestic market price of giritinib: How much does each box cost?
2026-02-01 22:25:32
Check Details
CALGB 10603/RATIFY 10-year follow-up: midostaurin versus placebo plus intensive chemotherapy in newly diagnosed FLT3-mutant AML
2026-02-01 22:25:32
Check Details
Why is cabergoline banned in China? An article reveals the reason!
2026-02-01 22:25:32
Check Details
Molotinib/mometinib side effects and solutions
2026-02-01 22:25:32
Check Details
Are Bitovil/Bikonprenol tablets classified as blocking drugs? Detailed explanation of mechanism of action and indications
2026-02-01 22:25:32
Check Details
Upadatinib and deuterated colexitinib are two large molecule drugs for the treatment of psoriatic arthritis.
2026-02-01 22:25:32
Check Details
Full analysis of the instructions for Apremilast/Apremilast tablets and a comprehensive medication guide!
2026-02-01 22:25:32
Check Details
What is the market price of a box of Valganciclovir?
2026-02-01 22:25:32
Check Details
Once you take aprexitentan, can you stop it for life? Medication cycle and precautions
2026-02-01 22:25:32
Check Details
In T2D, switching to tilsiparatide/tilpotide shows greater benefit than escalating dulaglutide
2026-02-01 22:25:32
Check Details
The current status of pitobrutinib/pitubrutinib being launched in China is revealed!
2026-02-01 22:25:32
Check Details
1
2
...
1464
1465
1466
1467
1468
1469
1470
...
10239
10240
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
2
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
3
Anagrelide Cautions and Contraindications: Allergy, Hepatic, Cardiac and Bleeding Risks
4
FDA Accelerated Approval of Voceryq: First Plasmid DNA Immunotherapy for Adult Recurrent Respiratory Papillomatosis
5
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
6
Revumenib: Key Considerations Before and During Treatment
7
Pacritinib in Myelofibrosis: Evidence on Spleen Volume Reduction and Symptom Control
8
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
9
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
10
Pomalidomide vs Thalidomide: IMiD Generation Gap and MM Use
11
Dasatinib: A BCR-ABL Targeted TKI, Not Conventional Chemo
12
Obeticholic Acid (OCA): FXR Therapy in PBC and Liver Safety Limits